Sunday, June 30, 2013

Women in their 30s and 40s are TWICE as likely to contract cancer than men | Mail Online


  • Women in their late 30s and early 40s are twice as likely as men to develop cancer, new figures have revealed.
  • Breast cancer is the main reason for the increased risk among women aged between 35 and 44, according to the data published by the Office for National Statistics (ONS).
  • This form of the disease accounted for 30.7 per cent of all new cancer cases recorded in 2011.

Gender disparity: Map shows have cancer rates among men and women diverge more as people age, with men having a 14 per cent greater lifetime risk
Gender disparity: Map shows how cancer rates among men and women diverge more as people age, with men having a 14 per cent greater lifetime risk
While the report found that women have a higher chance of cancer earlier in life, men have a higher lifetime risk of getting the disease, the study found. 
For men, the most common type of cancer was of the prostate, which accounted for 25.6 per cent of new cases.
The figures show there is little difference between men and women for other commonly reported cases of cancer.

    Lung cancer was the second most prevalent type of the disease in 2011, accounting for 13.8 per cent of new cases in men and 11.6 per cent among women.
    Bowel cancer was the third most common form of the disease, with rates of 13.6 per cent and 11.2 per cent among men and women, respectively.
    The data also shows that older people and those living in the north of the country have a higher risk of contracting the disease.
    Cancer incidence was higher than expected for both sexes in the north of England, and for women in the East Midlands and South West regions.
    In the older age groups, rates of cancer in 2011 were higher in males than in females - 37 per cent higher in those aged 65 to 69, and 63 per cent higher in those aged 85 and over.
    Cancers caused by unhealthy lifestyles, such as drinking and smoking, have seen a rise of up to two-thirds in the last decade. Malignant melanoma – the deadliest form of skin cancer, which affects many young people – rose more than any other type in the past decade, by 66 per cent.
    Rates: Map shows highest incidence of cancer among men
    Rates: Map shows highest incidence of cancer among men in cities in the north east and north west. Interactive map on the ONS website shows how rates for men and women have changed across the country
    Cancers to see a decline in the number of new reported cases in 2011 included ovarian and stomach cancers.
    Nick Orminston-Smith, statistical information manager at Cancer Research UK, told The Independent: 'Even though you're more likely to get breast cancer when you're older there are some younger women who contract it.
    'Overall, however, men are more likely to get cancer than women across all ages. You're about 14 per cent more likely to develop cancer at some point if you're a man.'
    In 2011, some 139,120 men in the UK were registered as having cancer, compared with 135,113 women. Figures for both genders are expected to rise with the inclusion of additional hospital admissions.
    Ciarán Devane, chief executive at Macmillan Cancer Support, pointed out in the newspaper that in the last ten years, cancer rates have soared by nearly a fifth. He said the figures were 'startling'.
    Mr Devaneadded that it was important to highlight that among cancer types there was a huge amount of variation and the reasons cancer affects some subgroup more than others were extremely complex and not fully understood.
    Cancer rates among men and women and across different forms of the disease
    Cancer rates among men and women and across different forms of the disease
    To view which areas in England have the highest rates of cancer, for men and women, visit the ONS website.

    Read more:
    Follow us: @MailOnline on Twitter | DailyMail on Facebook

    Thursday, June 27, 2013 | FoCP gives beneficiaries a taste of ‘life at the top’

    By Mariecar Jara-PuyodJune 27, 2013
     Print    Send to Friend

    DUBAI: Everybody, even the sick, should live life to the fullest.

    A special project of the UAE internationally-recognised charity organisation, Friends of Cancer Patients (FoCP), highlighted this on Wednesday, when 52 of its most active members in the last two years, spent a few hours to experience “life at the top” of world’s tallest structure, Burj Khalifa in Downtown Dubai.

    “Everybody, even those with diseases, should live life to the fullest and must be given access to quality life,” FOCP secretary general Dr Sawsan Al Mahdi told The Gulf Today.

    Also, the FOCP’s Pink Caravan-Medical and Awareness Programme director, Al Mahdi was interviewed before proceeding with the 52 members’ families and friends to the 124th floor of the 828 metre-high tower.

    Pink Caravan is the initiative that aims at enhancing cancer awareness and early detection, particularly breast cancer, through country-wide data collection.

    Al Mahdi elaborated that the Burj Khalifa trip, in coordination with the corporate social responsibility mission of the international real estate and property developer, Emaar, is part of FoCP’s beneficiaries’ bi-monthly activities.

    “For us, they are beneficiaries and today is another form of the psychological support we give them,” she said.

    Al Mahdi explained that psychological support is about encouraging the sick not to be “cocoons” but become active members of mainstream life because this helps them maintain their mental and physiological health.

    Mounira Abdul Karim from Syria has been living with breast cancer for the past five years and is an FoCP beneficiary since 2010.

    She heard about FoCP through a television programme, and she agreed with Al- Mahdi stating that “It is good to be with a group. I have become stronger in this journey.”

    Her nephew and niece had joined her, and it was clear that that they were excited about being with their aunt and the novelty of the trip.

    Another breast cancer survivor, Armida Valdez from the Philippines, underwent the sixth cycle of her chemotherapy in the UAE through the FoCP in 2010.

    She asserted that being among people in the mainstream and workforce, even while suffering from her illness, helped her to maintain positive feelings of self-worth and confidence.

    Valdez found that the FoCP was “very supportive,” and that the organisation does not discriminate.

    It was a confirmation of what Al Mahdi had earlier told newsmen that FoCP’s mission is to assist all cancer-stricken residents of the UAE regardless of age, creed and race.

    Emirati Amna Hamad Mohammad who is under treatment against leukaemia through FoCP and her 13-year-old daughter, Marwam, expressed happiness over their on Wednesday adventure.

    Both believe that everyone deserves to be happy.

    FoCP has so far helped over 900 cancer patients across the UAE for14 years under the patronage of Sheikha Jawaher Bint Mohammad Al Qasimi, wife of UAE Supreme Council Member and Ruler of Sharjah, Dr Sheikh Sultan Bin Mohammed Al Qasimi.

    Tuesday, June 25, 2013

    Friends of Cancer Patients launches ‘Breaking the Silence’ campaign

    Friends of Cancer Patients launches 
    ‘Breaking the Silence’ campaign
    Charitable society takes metastatic breast cancer patients into its fold

    For immediate release
    25 June 13

    After successful pan-UAE campaigns for awareness on early detectable cancers, the Friends of Cancer Patients (FoCP) charitable society is expanding its fold to include metastatic breast cancer patients – a stigmatised and often forgotten segment of community, usually living with advanced stages of cancer – through its nationwide campaign titled ‘Breaking the Silence’, launched under the Pink Caravan breast cancer initiative.

    Beginning with three key medical institutes across the UAE, the campaign aims to empower metastatic patients to lead full lives and mould public opinion about those touched by the disease.
    The events are being hosted at University Hospital Sharjah at 11 am on 27th June, Sheikh Khalifa Medical City, Abu Dhabi, at 12 pm on 30th  June and, Tawam Hospital, Al Ain, at 11am  on 2nd July, and will see a rallying of metastatic patients, physicians, social workers, nurses, and the media.

      Dr Sawsan Al Madhi, Secretary General for Friends of Cancer Patients (FoCP) charitable   society, said,
    “The FoCP has launched ‘Breaking the Silence’ as a metastatic breast cancer-focused pan-UAE campaign under its Pink Caravan breast cancer awareness initiative to highlight the plight of metastatic cancer patients in the community. These patients form a segment of the society that is most often sidelined from the mainstream activities of daily life, making it much harder for them to access employment opportunities, continue studies, or lead healthy social lives due to the stigma associated with cancer.”

    She went on to say, “The Friends of Cancer Patients and Pink Caravan, due to its collaboration and representation at international platforms, realised early on the need to create a platform for advanced or metastatic breast cancer patients and therefore ‘Breaking the Silence’ is being launched. The Friends of Cancer Patients, since its inception in 1999, has been supporting cancer patients and their families financially as well as emotionally, and to date has helped more than 900 patients in their challenge. Now, expanding on its past experiences, FoCP is planning to take metastatic cancer patients into its fold, and encourage, motivate and empower them to live life to the fullest.”
    “Our primary goal is to educate the public and media and through that, create widespread awareness about metastatic cancer  –  a stage of the disease where cancer cells have spread to other areas and is no longer localised– and encourage social acceptance for these patients. We look forward to a long and successful journey.”

    Dr Mohammad Jaloudi, Head of Oncology and Haematology Department at Tawam Hospital, said, “The importance of creating awareness about metastatic cancer patients cannot be stressed enough. Although, early detection and awareness programmes have done a great deal for patients in their early stages of cancer, metastatic cancer patients are more often sidelined, as they are considered to be in the final stages of their life. This is not true. What people usually don’t realise is that metastatic patients can live full lives for a long time, sometimes for years, with the help of new medical therapies and as such need to be taken back into the folds of society.”

    The three events have been organised in partnership with Novartis – a pharmaceutical company known for investing in innovative research for marginalised diseases.

    About Friends of Cancer Patients
    The Friends of Cancer Patients (FoCP) is a UAE based charitable society providing its services across the United Arab Emirates to all residents of the country.
    FoCP was established in late 1999 in accordance with the directives and under the patronage of Her Highness Sheikha Jawaher Bint Mohammed AI Qasimi, wife of His Highness Dr Sheikh Sultan bin Mohammed Al Qasimi, Member of the Supreme Council and Ruler of Sharjah, Chairperson of the Supreme Council for Family Affairs, Founder and royal Patron of the Friends of Cancer Patients charitable society. (FoCP).
    Being the leading cancer specific charity operating in the UAE, FoCP, an NGO and registered charity, has since its inception continuously delivered moral, financial, and clinical support to over 900 patients and their families, regardless of their nationality, gender, age, religion, or ethnicity. The primary focus is on promoting awareness around early detectable cancers within the UAE community. FoCP has also initiated numerous leading cancer focused awareness programmes targeting the community, which have become recognised locally, regionally, and internationally.
    FoCP is committed to helping cancer patients and their families get through the long and arduous journey of cancer treatment. Their motto is "We're with you". FoCP provides a broad spectrum of support including, covering treatment expenses for chemotherapy, radiation and other needed medications, in addition to expenses for investigative and surgical procedures. They also provide transportation and food allowances for underprivileged cancer patients, facilitate in sending patients abroad for treatment, provide prosthetic limbs, medical equipment, psychological and moral support for patients and their families.
    FoCP’s volunteer team consists of businessmen and women, doctors, nurses, students, and the families of patients from various nationalities who have undertaken the responsibility of helping and supporting cancer patients.  FoCP is constantly raising the bar and setting new targets to expand on its achievements to date and empower the community to change the cultural and social stigma associated with cancer.
    FoCP is a member and affiliate of a number of different organisations including, the Kuwait-based Gulf Federation for Cancer Control, the Union for International Cancer Control (UICC) based in Geneva Switzerland, and the US-Middle East Partnership for Breast Cancer Awareness and Research which is supported by the US Department of State’s Middle East Partnership Initiative (MEPI). FoCP has garnered widespread recognition and awards from numerous leading institutions, locally, regionally, and internationally for FoCP leading role in helping cancer patients and creating awareness about the disease.

    Metastatic Cancer Fact Sheet - National Cancer Institute

    “Friends of Cancer Patients (FoCP) charitable cancer society is expanding its fold to include metastatic breast cancer patients. Nationally launching ‘Breaking the Silence’ as a way to highlight the plight of metastatic cancer patients in the community, a segment of the society that is most often sidelined from the mainstream activities of daily life, isolating these patients. Our primary goal is to educate the public and media in a bid to create widespread awareness around metastatic cancer –  a stage of the disease where cancer cells are no longer localised – and strongly encourage social acceptance for these patients. The campaign aims to expand on its past experiences to encourage, motivate and empower patients to continue contributing meaningfully to society.”

    Metastatic Cancer

    Key Points

    • Metastatic cancer is cancer that has spread from the place where it first started to another place in the body.
    • Metastatic cancer has the same name and same type of cancer cells as the original cancer.
    • The most common sites of cancer metastasis are, in alphabetical order, the bone, liver, and lung.
    1. What is metastatic cancer?

      Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. A tumor formed by metastatic cancer cells is called a metastatic tumor or a metastasis. The process by which cancer cells spread to other parts of the body is also called metastasis.
      Metastatic cancer has the same name and the same type of cancer cells as the original, or primary, cancer. For example, breast cancer that spreads to the lung and forms a metastatic tumor is metastatic breast cancer, not lung cancer.
      Under a microscope, metastatic cancer cells generally look the same as cells of the original cancer. Moreover, metastatic cancer cells and cells of the original cancer usually have some molecular features in common, such as the expression of certain proteins or the presence of specific chromosome changes.
      Although some types of metastatic cancer can be cured with current treatments, most cannot. Nevertheless, treatments are available for all patients with metastatic cancer. In general, the primary goal of these treatments is to control the growth of the cancer or to relieve symptoms caused by it. In some cases, metastatic cancer treatments may help prolong life. However, most people who die of cancer die of metastatic disease.
    2. Can any type of cancer form a metastatic tumor?

      Virtually all cancers, including cancers of the blood and the lymphatic system (leukemiamultiple myeloma, and lymphoma), can form metastatic tumors. Although rare, the metastasis of blood and lymphatic system cancers to the lung, heart, central nervous system, and other tissues has been reported.
    3. Where does cancer spread?

      The most common sites of cancer metastasis are, in alphabetical order, the bone, liver, and lung. Although most cancers have the ability to spread to many different parts of the body, they usually spread to one site more often than others. The following table shows the most common sites of metastasis, excluding the lymph nodes, for several types of cancer:

      Cancer typeMain sites of metastasis*
      BladderBone, liver, lung
      BreastBone, brain, liver, lung
      ColorectalLiver, lung, peritoneum
      KidneyAdrenal gland, bone, brain, liver, lung
      LungAdrenal gland, bone, brain, liver, other lung
      MelanomaBone, brain, liver, lung, skin/muscle
      OvaryLiver, lung, peritoneum
      PancreasLiver, lung, peritoneum
      ProstateAdrenal gland, bone, liver, lung
      StomachLiver, lung, peritoneum
      ThyroidBone, liver, lung
      UterusBone, liver, lung, peritoneum, vagina
      *In alphabetical order. Brain includes the neural tissue of the brain (parenchyma) and the leptomeninges (the two innermost membranes—arachnoid mater and pia mater—of the three membranes known as the meninges that surround the brain and spinal cord; the space between the arachnoid mater and the pia mater contains cerebrospinal fluid). Lung includes the main part of the lung (parenchyma) as well as the pleura (the membrane that covers the lungs and lines the chest cavity).
    4. How does cancer spread?

      Cancer cell metastasis usually involves the following steps:
      • Local invasion: Cancer cells invade nearby normal tissue.
      • Intravasation: Cancer cells invade and move through the walls of nearby lymph vesselsor blood vessels.
      • Circulation: Cancer cells move through the lymphatic system and the bloodstream to other parts of the body.
      • Arrest and extravasation: Cancer cells arrest, or stop moving, in small blood vessels called capillaries at a distant location. They then invade the walls of the capillaries and migrate into the surrounding tissue (extravasation).
      • Proliferation: Cancer cells multiply at the distant location to form small tumors known as micrometastases.
      • Angiogenesis: Micrometastases stimulate the growth of new blood vessels to obtain a blood supply. A blood supply is needed to obtain the oxygen and nutrients necessary for continued tumor growth.
      Metastasis. Cancer cells invade lymph nodes and blood vessels near a tumor and spread to other parts of the body.
      Metastasis. Cancer cells invade lymph nodes and blood vessels near a tumor and spread to other parts of the body.
      Because cancers of the lymphatic system or the blood system are already present inside lymph vessels, lymph nodes, or blood vessels, not all of these steps are needed for their metastasis. Also, the lymphatic system drains into the blood system at two locations in the neck.
      The ability of a cancer cell to metastasize successfully depends on its individual properties; the properties of the noncancerous cells, including immune system cells, present at the original location; and the properties of the cells it encounters in the lymphatic system or the bloodstream and at the final destination in another part of the body. Not all cancer cells, by themselves, have the ability to metastasize. In addition, the noncancerous cells at the original location may be able to block cancer cell metastasis. Furthermore, successfully reaching another location in the body does not guarantee that a metastatic tumor will form. Metastatic cancer cells can lie dormant (not grow) at a distant site for many years before they begin to grow again, if at all.
    5. Does metastatic cancer have symptoms?

      Some people with metastatic tumors do not have symptoms. Their metastases are found by x-rays or other tests.
      When symptoms of metastatic cancer occur, the type and frequency of the symptoms will depend on the size and location of the metastasis. For example, cancer that spreads to the bone is likely to cause pain and can lead to bone fractures. Cancer that spreads to the brain can cause a variety of symptoms, including headaches, seizures, and unsteadiness. Shortness of breath may be a sign of lung metastasis. Abdominal swelling or jaundice (yellowing of the skin) can indicate that cancer has spread to the liver.
      Sometimes a person’s original cancer is discovered only after a metastatic tumor causes symptoms. For example, a man whose prostate cancer has spread to the bones in his pelvis may have lower back pain (caused by the cancer in his bones) before he experiences any symptoms from the original tumor in his prostate.
    6. Can someone have a metastatic tumor without having a primary cancer?

      No. A metastatic tumor is always caused by cancer cells from another part of the body.
      In most cases, when a metastatic tumor is found first, the primary cancer can also be found. The search for the primary cancer may involve lab tests, x-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, positron emission tomography (PET) scans, and other procedures.
      However, in some patients, a metastatic tumor is diagnosed but the primary tumor cannot be found, despite extensive tests, because it either is too small or has completely regressed. Thepathologist knows that the diagnosed tumor is a metastasis because the cells do not look like those of the organ or tissue in which the tumor was found. Doctors refer to the primary cancer as unknown or occult (hidden), and the patient is said to have cancer of unknown primary origin(CUP).
      Because diagnostic techniques are constantly improving, the number of cases of CUP is going down. More information can be found in the Carcinoma of Unknown Primary Treatment (PDQ®)summary, which is part of NCI’s comprehensive cancer information database.
    7. If a person who was previously treated for cancer gets diagnosed with cancer a second time, is the new cancer a new primary cancer or metastatic cancer?

      The cancer may be a new primary cancer, but, in most cases, it is metastatic cancer.
    8. What treatments are used for metastatic cancer?

      Metastatic cancer may be treated with systemic therapy (chemotherapybiological therapy,targeted therapyhormonal therapy), local therapy (surgery, radiation therapy), or a combination of these treatments. The choice of treatment generally depends on the type of primary cancer; the size, location, and number of metastatic tumors; the patient’s age and general health; and the types of treatment the patient has had in the past. In patients with CUP, it is possible to treat the disease even though the primary cancer has not been found.
    9. Are new treatments for metastatic cancer being developed?

      Yes, researchers are studying new ways to kill or stop the growth of primary cancer cells and metastatic cancer cells, including new ways to boost the strength of immune responses against tumors. In addition, researchers are trying to find ways to disrupt individual steps in the metastatic process.
      Before any new treatment can be made widely available to patients, it must be studied in clinical trials (research studies) and found to be safe and effective in treating disease. NCI and many other organizations sponsor clinical trials that take place at hospitals, universities, medical schools, and cancer centers around the country. Clinical trials are a critical step in improving cancer care. The results of previous clinical trials have led to progress not only in the treatment of cancer but also in the detection, diagnosis, and prevention of the disease. Patients interested in taking part in a clinical trial should talk with their doctor.
    Selected References
    1. Aragon-Ching JB, Zujewski J. CNS metastasis: an old problem in a new guise. Clinical Cancer Research 2007; 13(6):1644–1647.
       [PubMed Abstract]
    2. Berman AT, Thukral AD, Hwang W-T, Solin LJ, Vapiwala N. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment.Clinical Breast Cancer 2012; epub ahead of print.
       [PubMed Abstract]
    3. Breda A, Konijeti R, Lam JS. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Review of Anticancer Therapy 2007; 7(6): 847–862.
       [PubMed Abstract]
    4. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology 2000; 31(5):578–583.
       [PubMed Abstract]
    5. Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum 2012; 18(2):328–342.
      [PubMed Abstract]
    6. Coghlin C, Murray GI. Current and emerging concepts in tumour metastasis. Journal of Pathology 2010; 222(1):1–15.
       [PubMed Abstract]
    7. Deng J, Liang H, Wang D, et al. Investigation of the recurrence patterns of gastric cancer following a curative resection. Surgery Today 2011; 41(2):210–215.
       [PubMed Abstract]
    8. Disibio G, French SW. Metastatic patterns of cancer: results from a large autopsy study. Archives of Pathology & Laboratory Medicine 2008; 132(6):931–939. [PubMed Abstract]
    9. Grier J, Batchelor T. Metastatic neurologic complications of non-Hodgkin’s lymphoma. Current Oncology Reports 2005; 7(1):55–60.
       [PubMed Abstract]
    10. Groves MD. Leptomeningeal disease. Neurosurgery Clinics of America 2011; 22(1):67–78.
      [PubMed Abstract]
    11. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer2006; 106(7):1624–1633.
       [PubMed Abstract]
    12. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. Journal of Surgical Oncology 2004; 86(4):172–178.
       [PubMed Abstract]
    13. Leong SP, Cady B, Jablons DM, et al. Clinical patterns of metastasis. Cancer Metastasis Reviews2006; 25(2):221–232.
       [PubMed Abstract]
    14. Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma.Endocrine-Related Cancer 2008; 15(1):37–49.
       [PubMed Abstract]
    15. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization.Nature Reviews Cancer 2009; 9(4):274–284.
       [PubMed Abstract]
    16. Otto CM. Cardiac masses and potential cardiac “source of embolus.” In: Textbook of Clinical Echocardiography. 4th ed. Philadelphia: Elsevier, Inc., 2009.
    17. Roth ES, Fetzer DT, Barron BJ, et al. Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer 2009; 9:274.
       [PubMed Abstract]
    18. Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. Archives of Neurology 2004; 61(9):1423–1429.
       [PubMed Abstract]
    19. Schuchert MJ, Luketich JD. Solitary sites of metastatic disease in non-small cell lung cancer.Current Treatment Options in Oncology 2003; 4(1):65–79.
       [PubMed Abstract]
    20. Shinagare AB, Ramaiya NH, Jagannathan JP, et al. Metastatic pattern of bladder cancer: correlation with the primary characteristics of the primary tumor. American Journal of Roentgenology 2011; 196(1):117–122.
       [PubMed Abstract]
    21. Sohaib SA, Houghton SL, Meroni R, et al. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clinical Radiology 2007; 62(1):28–34.
       [PubMed Abstract]
    22. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research 2010; 70(14):5649–5669. [PubMed Abstract]
    23. Viadana E, Bross ID, Pickren JW. An autopsy study of the metastatic patterns of human leukemias. Oncology 1978; 35(2):87–96. [PubMed Abstract]
    24. Woodward PJ, Hosseinzadeh K, Saenger JS. From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. RadioGraphics 2004; 24(1):225–246.
       [PubMed Abstract]
    25. Yachida S, Iacobuzio-Donahue CA. The pathology and genetics of metastatic pancreatic cancer.Archives of Pathology & Laboratory Medicine 2009; 133(3):413–422.
       [PubMed Abstract]
    This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.

    High Blood Pressure; Hypertension; The Silent Killer - Please do share across your networks, education is needed about this killer!

    Wednesday, June 19, 2013

    FOCP to Attend the Third Global Breast Health Lecture Series, Abu Dhabi, June 23rd, 2013

    FOCP has been invited to speak about "The Role of Non Governmental Organizations" in enhancing early detection and treatment for breast cancer, at the 3rd Global Breast Health Lecture Series organized by Mafraq hospital.

    The event is targeted at health care givers and any staff working in breast care, so if you are interested to join check the agenda below for more information and RSVP to Normy Acosta 

    تلقت جمعية أصدقاء مرضى السرطان الدعوة للتحدث عن دور المؤسسات الغير حكومية في تعزيز الاكتشاف المبكر والعلاج لسرطان الثدي، وذلك من خلال سلسلة محاضرات صحة الثدي العالمية الثالثة والتي تنظمها مستشفى المفرق.

    ويستهدف هذا الحدث مقدمي الرعاية الصحية وأي من العاملين في مجال رعاية سرطان الثدي، وللمهتمين بحضور المحاضرات يمكنكم التحقق من جدول الأعمال أدناه للحصول على مزيد من المعلومات وللحجز يمكنكم الإتصال بـ نورمي أكوستا 

    Tuesday, June 18, 2013

    Cancer society looks for regulation of e-cigarettes | Irish Examiner

    The Irish Cancer Society says it cannot recommend electronic cigarettes as an alternative to tobacco until they are regulated in Ireland.
    The ICS has welcomed moves in Britain to class e-cigarettes as ‘medicines’ under proposals to tighten up the regulation of nicotine products. 

    Manufacturers will have to face tough tests before they can sell their e-cigarettes as ‘licensed products’ in Britain. 

    The move will also mean e-cigarettes can be prescribed by doctors in to help smokers cut down or quit. 

    An e-cigarette is an electronic inhaler that vaporises a liquid nicotine into an aerosol mist, simulating the act of tobacco smoking 

    However, an ICS spokeswoman said the body could not recommend e-cigarettes in the absence of appropriate regulation and evidence. 

    “Until the safety and efficacy of these products are established and we can be assured that they do not pose a hazard to a person’s health and well-being, we are unable to recommend them,” said the spokeswoman. 

    E-cigarettes are widely available in Ireland but there are no regulations setting down the provisions for their sale or advertising. 

    The Pharmaceutical Society of Ireland advised pharmacies two years ago that, in the absence of regulation, e-cigarettes should not be offered for sale in pharmacies. E-cigarettes are being offered for sale in Ireland in a wide variety of shops and online, and a number of people have claimed to have quit smoking since using them. 

    In December, the European Commission proposed an EU tobacco products directive, the aim of which is to reduce the numbers smoking. 

    The proposal, currently being considered by member states, recommends that nicotine containing products below a certain nicotine threshold, such as e-cigarettes, are allowed on the market but must feature health warnings. 

    A spokesman for the Department of Health said the proposal was being discussed in the European Parliament and Council of Ministers and the commission was hoping it would be adopted next year. 

    He said the Irish presidency was using its time as chair of the council of the EU to vigorously pursue measure to reduce the prevalence of smoking, particularly among young people. 

    The Irish Medicines Board taking part in the European discussions said e-cigarettes were not regulated under medicines or medical devices legislation unless they make medicinal claims. 

    Currently products that are presented for use in or to assist in smoking cessation, such as patches and gum, are regarded to be medicines and must be authorised by the IMB before being sold in Ireland. 

    © Irish Examiner Ltd. All rights reserved

    'via Blog this'